<DOC>
	<DOCNO>NCT02595996</DOCNO>
	<brief_summary>This study investigate safety efficacy propranolol treatment patient primary lymphedema . The primary goal ass patient tolerability increase dos propranolol . The secondary goal ass lymphedema symptom sign response propranolol treatment .</brief_summary>
	<brief_title>Propranolol Dose Escalation Lymphedema Patients</brief_title>
	<detailed_description>Lymphatic malformation ( LMs ) arise abnormal development lymphatic vasculature . Primary lymphedema consider form LM . Recently , result investigator ' laboratory demonstrate propranolol , pan beta-adrenergic receptor ( βAR ) antagonist , cytotoxic anti-proliferative effect cell isolated LM tissue . Preliminary result treat symptomatic LM patient propranolol dose range 0.7-1mg/kg/day demonstrate 70 % positive response rate , patient report improvement symptom . Propranolol use different indication many year . Propranolol accept use infant hemangiomas supraventricular tachycardia . Hemangeol approve FDA use infant hemangioma . However , βAR antagonist without potential adverse effect , include hypotension , bradycardia , hypoglycemia , bronchospasm , sleep disturbance . FDA-approved dose range treat hemangioma infant ( &gt; 5 week old , &gt; 2kg ) range 1-3mg/kg/day divided dos . Propranolol dose 4mg/kg/day used pediatric supraventricular tachycardia . Therefore , investigator 's experience propranolol use LM patient low end accept clinical indication . The investigator propose escalate propranolol dosages 3mg/kg/day study , well dose range currently use clinical setting . This dose range 0.7-1mg/kg/day chosen LM patient low end dose range infant treat propranolol problematic hemangioma , related vascular anomaly . At dose , significant hemodynamic adverse effect note LM patient . However , patient stop propranolol dose fell 0.7mg/kg/day , suffer rebound worsen symptom . Moreover , inflammatory event infection temporarily overcame effect 0.7-1mg/kg/day propranolol . Thus , unknown whether maximum propranolol efficacy achieve current dose range . The investigator propose examine whether optimized propranolol usage treatment LM patient achieve . The primary endpoint study ascertain whether LM patient tolerate high dos propranolol , measure know propranolol adverse effect patient-reported symptom . A secondary endpoint address whether patient-reported LM symptom quality life improve high dos propranolol ; objective finding LM size physical examination image study analyze well . In addition , LM tissue biopsy acquire patient propranolol treatment analyse disease progression .</detailed_description>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Primary lymphedema Measurable disease Adequate functional status : Karnofsky &gt; 50 % ( &gt; age 16 ) , Lanky &gt; 50 ( &lt; age 16 ) , No prior therapy within 4 week enrollment Adequate bone marrow , renal function , cardiac , pulmonary function , negative pregnancy test ( woman ) . Secondary lymphedema Patients already receive investigational drug Patients know contraindication receive propranolol Other medical comorbidities include limited : pheochromocytoma , bradycardia , bronchospasm/reactive airway disease , decompensated heart failure , heart block , ongoing active infection .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>